Showing 5601-5610 of 7598 results for "".
- Nevisense Detects Skin Barrier Damage In Skin Sampleshttps://practicaldermatology.com/news/nevisense-detects-skin-barrier-damage-in-skin-samples/2462031/Nevisense can measure skin barrier function in human excised skin samples, SciBase reports. For the study, Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice
- DEF, SDPA Call Attention to Heart Health for World Heart Dayhttps://practicaldermatology.com/news/def-sdpa-call-attention-to-heart-health-for-world-heart-day/2462027/The Dermatology Education Foundation (DEF) and the Society of Dermatology Physician Assistants (SDPA) are calling on NPs and PAs in dermatology to take charge of their own health and support peers in recognition of World Heart Day on September 29, 2023. “As nurse practitioner
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Cosmo, Glenmark Sign Distribution and License Agreements for Winlevi in Europe and South Africahttps://practicaldermatology.com/news/cosmo-glenmark-sign-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/2462024/Glenmark Pharmaceuticals Ltd., now has exclusive rights to commercialize Winlevi (clascoterone cream 1%) in 15 EU countries (Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal,
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- PFAS Exposure Linked to Melanoma in Womenhttps://practicaldermatology.com/news/pfas-exposure-linked-to-melanoma-in-women/2462011/Exposure to PFAS (per- and poly-fluoroalkyl substances) and phenols may be linked to diagnoses of melanoma and other cancers, new research suggests. Women who reported higher levels of exposure to PFDE, a long-chained PFAS compound, had double the odds of a previous melanoma diagnosis;
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P